Enhanced platelet IIb/IIIa inhibition with eptifibatide via high-dose, double-bolus dosing: Final results of the PRIDE study
Publication
, Journal Article
Gilchrist, IC; Thel, MC; Joseph, D; Zimmerman, HE; Jennings, LK; Kleiman, NS; Kerelakes, DJ; Talley, JD; O'Brien, MA; Lorenz, T; Tcheng, JE
Published in: CIRCULATION
October 27, 1998
Duke Scholars
Published In
CIRCULATION
ISSN
0009-7322
Publication Date
October 27, 1998
Volume
98
Issue
17
Start / End Page
844 / 845
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Gilchrist, I. C., Thel, M. C., Joseph, D., Zimmerman, H. E., Jennings, L. K., Kleiman, N. S., … Tcheng, J. E. (1998). Enhanced platelet IIb/IIIa inhibition with eptifibatide via high-dose, double-bolus dosing: Final results of the PRIDE study. CIRCULATION, 98(17), 844–845.
Gilchrist, I. C., M. C. Thel, D. Joseph, H. E. Zimmerman, L. K. Jennings, N. S. Kleiman, D. J. Kerelakes, et al. “Enhanced platelet IIb/IIIa inhibition with eptifibatide via high-dose, double-bolus dosing: Final results of the PRIDE study.” CIRCULATION 98, no. 17 (October 27, 1998): 844–45.
Gilchrist IC, Thel MC, Joseph D, Zimmerman HE, Jennings LK, Kleiman NS, et al. Enhanced platelet IIb/IIIa inhibition with eptifibatide via high-dose, double-bolus dosing: Final results of the PRIDE study. CIRCULATION. 1998 Oct 27;98(17):844–5.
Gilchrist, I. C., et al. “Enhanced platelet IIb/IIIa inhibition with eptifibatide via high-dose, double-bolus dosing: Final results of the PRIDE study.” CIRCULATION, vol. 98, no. 17, LIPPINCOTT WILLIAMS & WILKINS, Oct. 1998, pp. 844–45.
Gilchrist IC, Thel MC, Joseph D, Zimmerman HE, Jennings LK, Kleiman NS, Kerelakes DJ, Talley JD, O’Brien MA, Lorenz T, Tcheng JE. Enhanced platelet IIb/IIIa inhibition with eptifibatide via high-dose, double-bolus dosing: Final results of the PRIDE study. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 1998 Oct 27;98(17):844–845.
Published In
CIRCULATION
ISSN
0009-7322
Publication Date
October 27, 1998
Volume
98
Issue
17
Start / End Page
844 / 845
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology